Isofol Medical AB is a biotech company, which engages in the development of the cancer drug Arfolitixorin, intended primarily for the treatment of colorectal cancer. The company was founded in 2008 by Bengt Gustaf Gustavsson and is headquartered in Gothenburg, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company